GSK outlines CFO succession
This article was originally published in The Tan Sheet
Executive SummaryJulian Heslop will retire at the end of March 2011 as GlaxoSmithKline's chief financial officer and executive director to be succeeded by Simon Dingemans. The U.K. pharma said Sept. 8 Dingemans has 25 years of experience in investment banking and has worked closely with GSK. He currently serves as managing director and partner at Goldman Sachs and previously headed the investment bank's European mergers and acquisitions business. Dingemans will support the company's "strategy to grow and diversify GSK's business through organic means and bolt-on acquisitions," said CEO Andrew Witty. Heslop has been the firm's CFO for five years
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.